Volume 12 Supplement 2
Pooled analysis of safety for micafungin
© BioMed Central Ltd 2008
Published: 13 March 2008
We characterised the safety of MICA by analysing pooled adverse event (AE) data from 17 clinical studies conducted worldwide. All patients (n = 3,028) received ≥ 1 dose of intravenous MICA; a median daily dose of 100 mg for adults and 1.5 mg/kg for children over a mean duration of 18 and 29 days, respectively.
This large database with more than 3,000 patients demonstrated a favourable clinical safety profile for micafungin.
- Kuse ER, et al: Lancet. 2007, 369: 1519-1527. 10.1016/S0140-6736(07)60605-9.PubMedView ArticleGoogle Scholar
- de Wet NT, et al: Aliment Pharmacol Ther. 2005, 21: 899-907. 10.1111/j.1365-2036.2005.02427.x.PubMedView ArticleGoogle Scholar
- van Burik JA, et al: Clin Infect Dis. 2004, 39: 1407-1416. 10.1086/422312.PubMedView ArticleGoogle Scholar
- Pappas PG, et al: Clin Infect Dis. 2007, 45: 883-893. 10.1086/520980.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd.